EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Central Nervous System Involvement in Extranodal NK/T-Cell Lymphoma: Risk Stratification, Prophylaxis, and Management

Jingkai Song, Xinxiu Liu, Tao Liu, Liling Zhang, Fang Zhu

Cancers · 19.11.2026 · 18 (22) · 3706

DOI: 10.3390/cancers18223706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 19.11.2026. Verfasst von Jingkai Song und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of Hubei Province.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extranodal NK/T-cell lymphoma (ENKTL) is an Epstein–Barr virus (EBV)-driven malignancy concentrated in East Asia and Latin America. Central nervous system (CNS) involvement occurs in 1.3–5.8% of largely unselected cohorts and carries a median survival of a few months. It has been reviewed only within broader T-cell scopes, never with ENKTL as the subject, although ENKTL is the only subtype in that lineage with its own validated CNS relapse model. Cohorts of more than 4500 patients support four observations. Incidence estimates are barely comparable because the CNS endpoint differs in almost every study; the reported range probably understates the true burden through incomplete cerebrospinal fluid (CSF) ascertainment. Meanwhile, two competing-risk analyses indicate that truncation of the observation window conceals little. Risk is concentrated in a definable subgroup: CNS-PINK, a two-point index for NK-cell lymphoma, separates a high-risk group with 2-year CNS relapse of 13.9–22.8% from a low-risk group at 4.1–4.5%, yet it assigns no patient with localized disease to that group, and a pan-T/NK model (CITI) did not select ENKTL as a risk histology. Prophylaxis evidence is internally inconsistent: the only positive signal, systemic intermediate-dose methotrexate, came from one training cohort and did not reach significance on validation, against uniformly conservative guidelines. Diagnosis is shifting from cytology toward CSF flow cytometry and circulating tumor DNA. Prophylaxis can neither be recommended nor withheld on current evidence; for each of the three decisions, we set out what the literature reaches and how far.

Förderung

  • the Natural Science Foundation of Hubei Province

Zitieren

APA

Song, J., Liu, X., Liu, T., Zhang, L., & Zhu, F. (2026). Central Nervous System Involvement in Extranodal NK/T-Cell Lymphoma: Risk Stratification, Prophylaxis, and Management. Cancers, 18(22), 3706. https://doi.org/10.3390/cancers18223706

Vancouver

Song J, Liu X, Liu T, Zhang L, Zhu F. Central Nervous System Involvement in Extranodal NK/T-Cell Lymphoma: Risk Stratification, Prophylaxis, and Management. Cancers. 2026;18(22):3706. doi:10.3390/cancers18223706

BibTeX
@article{Song2026,
  author = {Song, Jingkai and Liu, Xinxiu and Liu, Tao and Zhang, Liling and Zhu, Fang},
  title = {Central Nervous System Involvement in Extranodal NK/T-Cell Lymphoma: Risk Stratification, Prophylaxis, and Management},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3706},
  doi = {10.3390/cancers18223706}
}
Kostenlos starten →